Heart biomarkers as prognostic tools for chronic thromboembolic pulmonary hypertension: A step forward by the fatty acid-binding protein

European Respiratory Journal

Volumn 31, Issue 5, 2008, Pages 915-917

  Orfanos, S E ^a,b   Zakynthinos, S ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; BRAIN NATRIURETIC PEPTIDE; FATTY ACID BINDING PROTEIN; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; SILDENAFIL; TROPONIN; BIOLOGICAL MARKER;

DISEASE COURSE; DISEASE MARKER; DISEASE PREDISPOSITION; EDITORIAL; ENDARTERECTOMY; FATTY ACID METABOLISM; HEART FAILURE; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HUMAN; LUNG EMBOLISM; LUNG HEMODYNAMICS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; RISK ASSESSMENT; BLOOD; NOTE; PATHOPHYSIOLOGY; PULMONARY ARTERY;

BIOLOGICAL MARKERS; ENDARTERECTOMY; FATTY ACID-BINDING PROTEINS; HUMANS; HYPERTENSION, PULMONARY; PROGNOSIS; PULMONARY ARTERY; PULMONARY EMBOLISM;

EID: 47049106681     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00031608     Document Type: Editorial

References (18)

1. Lang IM. Chronic thromboembolic pulmonary hypertension: not so rare after all. N Engl J Med 2004; 350: 2236-2238.
2. Auger WA, Kerr KM, Kim NHS, Ben-Yehuda O, Knowlton KU, Fedullo PF. Chronic thromboembolic pulmonary hypertension. Cardiol Clin 2004; 22: 453-466.
3. Hoeper MM, Mayer E, Simonneau G, Rubin LJ. Chronic thromboembolic pulmonary hypertension. Circulation 2006; 113: 2011-2020.
4. Moser KM, Bloor CM. Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension. Chest 1993; 103: 685-692.
5. Bresser P, Pepke-Zaba J, Jais X, Humbert M, Hoeper MM. Medical therapies for chronic thromboembolic pulmonary hypertension. An evolving treatment paradigm. Proc Am Thorac Soc 2006; 3: 594-600.
6. Condliffe R, Kiely DG, Gibbs JS, et al. Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2008 [Epub ahead of print PMID: 18292468].
7. Snow JL, Kawut SM. Surrogate end points in pulmonary arterial hypertension: assessing the response to therapy. Clin Chest Med 2007; 28: 75-89.
8. Lankeit M, Dellas C, Panzenböck A, et al. Heart-type fatty acid-binding protein for risk assessment of chronic thromboembolic pulmonary hypertension. Eur Respir J 2008; 31: 1024-1029.
9. Pelsers MM, Hermens WT, Glatz JF. Fatty acid-binding proteins as plasma markers of tissue injury. Clinica Chimica Acta 2005; 352: 15-35.
10. Alhadi HA, Fox KA. Do we need additional markers of myocyte necrosis: the potential value of heart fatty acid-binding protein. QJM 2004; 97: 187-198.
11. O'Donoghue M, de Lemos JA, Morrow DA, et al. Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes. Circulation 2006; 114: 550-557.
12. Kilcullen N, Viswanathan K, Das R, et al. Heart-type fatty acid-binding protein predicts long-term mortality after acute coronary syndrome and identifies high-risk patients across the range of troponin values. J Am Coll Cardiol 2007; 50: 2061-2067.
13. Mad P, Domanovits H, Fazelnia C, et al. Human heart-type fatty-acid-binding protein as a point-of-care test in the early diagnosis of acute myocardial infarction. QJM 2007; 100: 203-210.
14. Niizeki T, Takeishi Y, Arimoto T, et al. Persistently increased serum concentration of heart-type fatty-acid-binding protein predicts adverse clinical outcomes in patients with chronic heart failure. Circ J 2008; 72: 109-114.
15. Puls M, Dellas C, Lankeit M, et al. Heart-type fatty acid-binding protein permits early risk stratification of pulmonary embolism. Eur Heart J 2007; 28: 224-229.
16. Kaczynska A, Pelsers MM, Bochowicz A, Kostrubiec M, Glatz JFC, Pruszczyk P. Plasma heart-type fatty acid binding protein is superior to troponin and myoglobin for rapid risk stratification in acute pulmonary embolism. Clinica Chimica Acta 2006; 371: 117-123.
17. Torbicki A, Kurzyna M, Kuca P, et al. Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. Circulation 2003; 108: 844-848.
18. Reesink HJ, Tulevski II, Marcus JT, et al. Brain natriuretic peptide as noninvasive marker of the severity of right ventricular dysfunction in chronic thromboembolic pulmonary hypertension. Ann Thorac Surg 2007; 84: 537-543.